Suppliers / Urquima

Urquima

Spain 31 employees 2 duplicate records merged Updated 9 July 2026

Urquima is an API manufacturer based in Spain. It holds 4 active US drug master files across a filed portfolio of 4 molecules. Its filings concentrate with AIFA (IT), INFARMED (PT) and EMA. Its most recent recorded inspection, by US FDA, closed on 21 October 2021 as VAI.

4
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
22
filings across 4 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 21 October 2021 VAI US FDA
  • 21 September 2017 VAI US FDA
  • 29 September 2016 VAI US FDA
  • 4 April 2014 VAI US FDA
  • 17 June 2011 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Spain, Spain 3002808432

What they file, and where

Molecule Regulators Docs
Azelastine SFDA (Saudi Arabia), US FDA 2
Glipizide US FDA 1
Ivabradine US FDA 1
Rupatadine US FDA 1

Also appears on these molecule pages

Azelastine API Glipizide API Ivabradine API Rupatadine API

Filings and GMP by regulator

Regulator Filings GMP certificates
AIFA (IT) 11 None
INFARMED (PT) 6 None
EMA 3 None
AEMPS (ES) 2 None

Comparing suppliers?

Choose your molecules and target markets. Urquima comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 21 October 2021.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability